CD8A and breast cancer: Both in vitro and in vivo results revealed that the platform effectively reduced the proportions of viable BC cells and immunosuppressive cells (including MDSCs, Tregs, M2 TAMs, and exhausted T cells), stimulated DC maturation, and subsequently stimulated CD8+ T cell activation.